Phase 1 trial demonstrates a new mRNA vaccine's efficacy in adults, indicating promising outcomes for future use.
By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg).
No takes yet. Share an insight, caveat, or question.
Rego et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: